Truncating variants in the SHANK1 gene are associated with a spectrum of neurodevelopmental disorders
- PMID: 34113010
- PMCID: PMC8487955
- DOI: 10.1038/s41436-021-01222-w
Truncating variants in the SHANK1 gene are associated with a spectrum of neurodevelopmental disorders
Abstract
Purpose: In this study, we aimed to characterize the clinical phenotype of a SHANK1-related disorder and define the functional consequences of SHANK1 truncating variants.
Methods: Exome sequencing (ES) was performed for six individuals who presented with neurodevelopmental disorders. Individuals were ascertained with the use of GeneMatcher and Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources (DECIPHER). We evaluated potential nonsense-mediated decay (NMD) of two variants by making knock-in cell lines of endogenous truncated SHANK1, and expressed the truncated SHANK1 complementary DNA (cDNA) in HEK293 cells and cultured hippocampal neurons to examine the proteins.
Results: ES detected de novo truncating variants in SHANK1 in six individuals. Evaluation of NMD resulted in stable transcripts, and the truncated SHANK1 completely lost binding with Homer1, a linker protein that binds to the C-terminus of SHANK1. These variants may disrupt protein-protein networks in dendritic spines. Dispersed localization of the truncated SHANK1 variants within the spine and dendritic shaft was also observed when expressed in neurons, indicating impaired synaptic localization of truncated SHANK1.
Conclusion: This report expands the clinical spectrum of individuals with truncating SHANK1 variants and describes the impact these variants may have on the pathophysiology of neurodevelopmental disorders.
© 2021. The Author(s), under exclusive licence to the American College of Medical Genetics and Genomics.
Conflict of interest statement
Conflicts of Interest
Aida Telegrafi and Richard Person are employees of GeneDx, Inc. David Goldstein is a founder of and holds equity in Q State Biosciences and Praxis Therapeutics; holds equity in Apostle Inc., and serves as a consultant to AstraZeneca, Gilead Sciences, GoldFinch Bio and Gossamer Bio. No other authors have conflicting interests to disclose.
Figures




References
Web Resources
-
- ClinVar browser: http://www.ncbi.nlm.nih.gov/clinvar/
-
- Consensus Coding Sequence (CCDS), https://www.ncbi.nlm.nih.gov/CCDS/
-
- Ensembl genome assembly GRCh37: http://grch37.ensembl.org/Homo_sapiens/Info/Index.
-
- Ensembl Variant Effect Predictor (VEP): http://grch37.ensembl.org/Homo_sapiens/Tools/VEP.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials